Structure Therapeutics is presenting five studies on obesity and diabetes at a conference. The event is also expected to feature presentations from other companies, including Lilly and Novo, which are developing competing treatments. The conference may shed light on the effectiveness of various weight-loss and diabetes drugs, potentially impacting the market for GLP-1 treatments.